VANCOUVER, BC, Feb. 5, 2021 /PRNewswire/ - InMed
Pharmaceuticals Inc. ("InMed" or the "Company") (NASDAQ: INM)
(TSX: IN), a clinical-stage pharmaceutical company developing
medications targeting diseases with high unmet medical need and
leading the way in the clinical development of cannabinol ("CBN"),
will report financial results for the second quarter of
fiscal year 2021 ending December 31,
2020, on Thursday, February 11,
2021.
Conference Call & Webcast1:
|
Thursday, February
11, 2021 at 8:30 AM Pacific Time, 11:30 AM Eastern Time
|
|
Local -
Toronto
|
(+1)
416-764-8609
|
|
Local -
Vancouver
|
(+1)
778-383-7417
|
|
Toll Free - North
America
|
(+1)
888-390-0605
|
|
Conference
ID:
|
19917866
|
|
Webcast:
https://produceredition.webcasts.com/starthere.jsp?ei=1425283&tp_key=9f171376cb
|
|
(1Webcast replay available for 90
days)
|
Dial-In Replays2:
|
Toronto:
|
(+1)
416-764-8677
|
|
North America (Toll
Free):
|
(+1)
888-390-0541
|
|
Playback
Passcode:
|
917866 #
|
|
(2Dial-in replay available until
February 18, 2021)
|
The Company's full financial statements and related MD&A for
the second quarter December 31, 2020
will be available at
www.inmedpharma.com, www.sedar.com and at
www.sec.gov on February 11,
2021.
About InMed: InMed Pharmaceuticals is a clinical-stage
pharmaceutical company developing a pipeline of cannabinoid-based
medications, initially focused on the therapeutic benefits of
cannabinol (CBN) in diseases with high unmet medical need. The
Company is dedicated to delivering new therapeutic alternatives to
patients that may benefit from cannabinoid-based medicines. For
more information, visit www.inmedpharma.com.
Cautionary Note Regarding Forward-Looking
Information:
This news release contains "forward-looking information" and
"forward-looking statements" (collectively, "forward-looking
information") within the meaning of applicable securities
laws. Forward-looking information is based on management's
current expectations and beliefs and is subject to a number of
risks and uncertainties that could cause actual results to differ
materially from those described in the forward-looking
statements. Forward-looking information in this news release
includes statements about: delivering new therapeutic alternatives
to patients that may benefit from cannabinoid-based
medicines; developing a pipeline of cannabinoid-based
medications, initially focused on the therapeutic benefits of
cannabinol; leading the way in the clinical development of
cannabinol; and reporting financial results on February 11, 2021.
All forward-looking information herein is qualified in its
entirety by this cautionary statement, and InMed disclaims any
obligation to revise or update any such forward-looking information
or to publicly announce the result of any revisions to any of the
forward-looking information contained herein to reflect future
results, events or developments, except as required by law.
NEITHER THE TORONTO
STOCK EXCHANGE NOR ITS REGULATIONS
SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE
ADEQUACY OR ACCURACY OF THIS RELEASE.
View original
content:http://www.prnewswire.com/news-releases/inmed-pharmaceuticals-to-report-second-quarter-fiscal-2021-financial-results-301223390.html
SOURCE InMed Pharmaceuticals Inc.